vida: extract claims from 2026-04-01-natlawreview-fda-glp1-compounding-april-clarification

- Source: inbox/queue/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md

@@ -10,7 +10,7 @@ agent: vida
 sourced_from: health/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md
 scope: structural
 sourcer: KFF Health Policy
-related: ["generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost"]
+related: ["generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access", "medicare-glp1-bridge-program"]
 ---
 
 # Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics
@@ -23,3 +23,10 @@ The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion o
 **Source:** KFF 2025 poll demographic breakdown
 
 Age 65+ adults show only 9% GLP-1 usage compared to 22% for ages 50-64, directly reflecting Medicare's statutory exclusion of weight-loss drugs. This creates a sharp discontinuity at the Medicare eligibility threshold despite this population having the highest obesity burden and worst health outcomes. The demographic pattern confirms that structural coverage exclusions, not clinical need, determine access.
+
+
+## Supporting Evidence
+
+**Source:** National Law Review, FDA April 1 2026 503A/503B distinction
+
+The FDA's April 2026 clarification on compounded GLP-1s demonstrates regulatory design that systematically prevents scale: 503B facilities (capable of bulk production) are prohibited from compounding semaglutide/tirzepatide, while 503A pharmacies (state-regulated, small-scale) retain only a 4-prescription/month safe harbor. This regulatory architecture ensures that the affordable access pathway ($99/month compounded semaglutide) cannot serve population-scale demand, reproducing the access hierarchy through enforcement mechanics rather than explicit coverage exclusions.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -74,3 +74,10 @@ WHO explicitly states that current global access and affordability for GLP-1s ar
 **Source:** ICER Final Evidence Report, December 2025
 
 ICER report documents the access inversion at policy level: California Medi-Cal (serving lowest-income population) eliminated coverage January 2026 despite 14-0 clinical evidence. Medicare coverage restricted to cardiovascular risk indication, excluding pure obesity. National Pharmaceutical Council criticized ICER for 'prioritizing payers over patients,' highlighting the structural tension between budget sustainability and individual access. The 14-0 clinical verdict combined with simultaneous coverage elimination is the clearest expression of structural misalignment.
+
+
+## Extending Evidence
+
+**Source:** National Law Review, FDA April 1 2026 guidance
+
+FDA April 1, 2026 clarification establishes that 503A pharmacies retain a narrow safe harbor for compounded semaglutide (4 or fewer prescriptions per month with individualized clinical justification), while 503B outsourcing facilities are effectively prohibited. This creates a structural constraint where the $99/month compounding channel remains technically legal but architecturally prevented from scaling to population-level access. The 4-prescription/month limit is explicitly designed for rare clinical exceptions, not mass access, making 2031-2033 patent expiry the earliest realistic systemic access event for low-income populations.

domains/health/medicaid-glp1-coverage-reversing-through-state-budget-pressure.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-22-kff-medicaid-glp1-coverage-13-states.md
 scope: structural
 sourcer: KFF
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
 ---
 
 # State Medicaid budget pressure is actively reversing GLP-1 obesity coverage gains with California and three other states eliminating coverage in 2025-2026
@@ -31,3 +31,10 @@ Four states actively eliminated GLP-1 obesity coverage in 2025-2026: California,
 **Source:** ICER White Paper April 2025, BCBS MA financial data
 
 The >10x PMPM increase in employer plans (2023-2024) is steeper than California's Medi-Cal $85M → $680M projection over 4 years (~8x). BCBS MA's $400M operating loss driven primarily by GLP-1s demonstrates that the fiscal pressure forcing coverage elimination is not unique to Medicaid—commercial payers face the same solvency threat.
+
+
+## Extending Evidence
+
+**Source:** National Law Review, FDA compounding enforcement timeline
+
+As Medicaid coverage contracts and the compounding channel faces systematic closure (503A limited to 4 Rx/month, 503B effectively prohibited as of April 2026), the US GLP-1 access barrier is becoming more permanent through 2031, not less. The regulatory trajectory shows FDA enforcement escalating from grace period deadlines (April/May 2025) to 'decisive enforcement action' (February 2026) to narrow safe harbor clarification (April 2026), eliminating the last sub-$200/month access pathway at scale.

inbox/archive/health/2026-04-01-natlawreview-fda-glp1-compounding-april-clarification.md

@@ -7,9 +7,12 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: legal-analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-27
 priority: high
 tags: [glp-1, compounding-pharmacy, FDA, enforcement, semaglutide, access, regulatory, 503A, 503B]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content